Fierce Biotech News & Reports
Dec 18, 2024 · Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on Fierce Biotech as their must-read source for the latest news, analysis and data in the world of biotech ...
A look at the R&D landscape in obesity, led by GLP-1s - Fierce …
Mar 19, 2024 · If you’re feeling like overnight obesity became the indication du jour, you’re not alone. Novo Nordisk was granted approval for semaglutide to be marketed as Wegovy for chronic weight ...
Introducing Fierce Biotech's 2024 Fierce 15
One of our Fierce 15 honorees dove deep into the ocean for inspiration from the sea squirt to develop new human therapeutics. Another thought the adorable 13-lined ground squirrel, with its polka ...
Fierce Biotech Layoff Tracker 2024
Dec 19, 2024 · Dec. 11 - Nvelop Therapeutics / Chroma Medicine: As part of their merger to form new Boston-based biotech nChroma Bio, both Nvelop and Chroma have shed an undisclosed number of employees.Story ...
Biotech | Fierce Biotech
Oct 28, 2024 · Humacyte’s tissue-based Symvess is designed to be universally implantable for patients facing the loss of a limb.
Genentech inks $850M upfront deal for Regor's CDK inhibitors
Sep 30, 2024 · Genentech is paying $850 million upfront for Regor Pharmaceuticals’ portfolio of CDK inhibitors, taking ownership of a breast cancer candidate that has shown signs of single-agent efficacy in ...
FDA approves Exact Sciences’ next-gen Cologuard Plus home test
Oct 4, 2024 · Ten years after first collecting an FDA approval, it’s time for version number two. Exact Sciences has received an agency green light for Cologuard Plus, the next generation of its mainstay, at ...
MedTech | Fierce Biotech
Dec 18, 2024 · A look back at our top stories of 2024 sees them fall into two major themes: promise, and a realignment of expectations.
Vertex pain data: Combo results, Vicodin miss and stellar safety
Oct 21, 2024 · Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match ...
Regeneron to fill gaps in obesity, break ground in cell therapy
Feb 2, 2024 · Regeneron wants to improve on obesity care with a muscle-preservation approach, while elsewhere, the biopharma charts a new course in cell therapy.